| ²é¿´: 1284 | »Ø¸´: 6 | |||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | |||
[½»Á÷]
ÖÐÒëÓ¢£¨Ò©´ú·½ÃæµÄ£©
|
|||
|
¶à¼ÁÁ¿¿Ú·þ10mgÁ½ÖÖÖÆ¼Á£¬Ã¿ÈÕÒ»´Î£¬Ã¿´Î10mg£¬ÓÚ·þÒ©ºóµÚ4ÌìѪҩŨ¶È´ïÎÈ̬¡£Á½ÖÖÖÆ¼ÁµÄFֵΪ98.9%¡À7.9%£¬²ÎÊýTmax£¬Cmax£¬Cmin£¬AUCss£¬AUMCss£¬MRT£¬FIµÈÖ÷ÒªÒ©´ú²ÎÊý½Ó½ü£¬¾·½²îÏÔʾÎÞÏÔÖøÐÔ²îÒ죬½øÒ»²½¾Ë«µ¥²àt¼ìÑéºÍ£¨1-2a£©ÖÃÐÅÇø¼ä·ÖÎöÏÔʾҩ´ú¶¯Á¦Ñ§²ÎÊý½ÓÊÜÉúÎïµÈЧÐÔ¼ÙÉ裬˵Ã÷Á½ÖÖÖÆ¼ÁµÈЧ¡£ ÁÙ´²¹Û²ì£¬ÊÔÑéÆÚ¼äδ¼û²»Á¼·´Ó¦£¬ÎÞÖÐ;ÖÕÖ¹ÊÔÑéµÄÊÜÊÔÕß¡£ ÌåÄÚÍâÏà¹ØÐÔ ÌåÍâÈܳöÊý¾Ý ÒÀ¾ÝÑÐÖÆµ¥Î»Öƶ¨µÄÊͷŶȷ½·¨²â¶¨ÊÔÑ黺ÊͽºÄÒµÄÌåÍâÈܳöÊý¾ÝÈç±í ÌåÄÚÎüÊÕÊý¾Ý ÒÔWanger-Nelson·¨¼ÆËãÊÔÑéÓûºÊͽºÄÒ²»Í¬Ê±¼äµÄÌåÄÚÎüÊÕÊý¾Ý£¬½á¹ûÈç±í ÌåÄÚÎüÊÕÊý¾ÝÓëÌåÍâÈܳö·ÖÊýµÄÏà¹ØÐÔÁ¼ºÃ£¬Ïà¹Ø·½³ÌÈçÏ£º ÌåÄÚÎüÊÕÁ¿%=1.455*ÌåÍâÈܳöÁ¿-12.23 r=0.9638 |
» ²ÂÄãϲ»¶
²ÄÁÏר˶ӢһÊý¶þ306
ÒѾÓÐ5È˻ظ´
085600²ÄÁÏÓ뻯¹¤µ÷¼Á 324·Ö
ÒѾÓÐ9È˻ظ´
0703»¯Ñ§µ÷¼Á
ÒѾÓÐ12È˻ظ´
0703»¯Ñ§ 305Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
0703»¯Ñ§µ÷¼Á£¬Çó¸÷λÀÏʦÊÕÁô
ÒѾÓÐ10È˻ظ´
271²ÄÁϹ¤³ÌÇóµ÷¼Á
ÒѾÓÐ5È˻ظ´
281Çóµ÷¼Á£¨0805£©
ÒѾÓÐ16È˻ظ´
304Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
²ÄÁϹ¤³Ìר˶µ÷¼Á
ÒѾÓÐ6È˻ظ´
Ò»Ö¾Ô¸Ìì´ó²ÄÁÏÓ뻯¹¤£¨085600£©×Ü·Ö338
ÒѾÓÐ4È˻ظ´
» ÇÀ½ð±ÒÀ²£¡»ØÌû¾Í¿ÉÒԵõ½:
Çൺ¸ßУ2026ÕÐÉú˶ʿÑо¿Éú
+5/840
³ÖÐø´´ÒµÕߣ¬A8ÀëÒìÄÐÕ÷»é£¬ÊÂÒµÓöµ½Æ¿¾±£¬Ñ°ÕÒ´´ÒµÉú»î°éÂÂ
+1/482
Æí¸£2026¹ú»ùÃæÉÏÏîÄ¿
+5/345
ÎïÀíѧ µ÷¼Á
+1/85
»ªÄÏʦ·¶´óѧ£¨211£©²©Ê¿ÕÐÉú- µç×Ó¡¢×Ô¶¯»¯¡¢»úе¡¢ÉúÎïѧ¡¢ÎïÀíÏà¹Ø×¨Òµ
+2/42
ɽ¶«Ê¦·¶´óѧÓлú»¯Ñ§×¨ÒµºúÖÒÑàÀÏʦ¿ÎÌâ×éÕÐÊÕ2026½ì˶ʿÑо¿ÉúÒÔ¼°µ÷¼ÁÉú
+1/40
ºþ±±¹¤Òµ´óѧ ÉúÃü¿ÆÑ§Ó뽡¿µÑ§Ôº ¿ÎÌâ×éÕÐÊÕ2026¼¶Ê³Æ·/ÉúÎï·½Ïò˶ʿ
+1/35
Î÷±±¹¤Òµ´óѧ¹â×ÓѧÑо¿ÍÅ¶Ó³ÏÆ¸²©Ê¿ºó£¡
+2/34
Çൺ´óѧ̩ɽѧÕß¿ÎÌâ×éÕÐ2026ÄêÉêÇ뿼ºËÖÆ²©Ê¿
+1/33
ÖпÆÔºÉú̬»·¾³Ñо¿ÖÐÐĹúÖØÊµÑéÊÒÕÐÆ¸¿Í×ùÑо¿Éú1-2Ãû
+1/31
·ÄÖ¯¿ÆÑ§Ó빤³Ì¡¢²ÄÁÏ»¯¹¤·½ÏòÕÐÊÕÑо¿Éú
+1/28
±¨ÃûͨµÀ¿ªÆôÀ²£¡Õã½ÖÐÒ½Ò©´óѧ¸±Ð£³¤ÍŶÓÕÐÆ¸Ò©Ñ§/ÉúÎïÐÅϢѧµÈ·½Ïò¸ßУ½Ìʦ7Ãû(µØµ
+1/21
Äϲýº½¿Õ´óѧ´úÍþÁ¦½ÌÊÚÕÐÊÕ¹â´ß»¯ºÍ¹âÈÈ´ß»¯Ñо¿·½Ïò²©Ê¿Éú
+1/9
211/˫һÁ÷---ʯºÓ×Ó´óѧ---Óлú»¯Ñ§·½ÏòÕе÷¼ÁÉú
+1/9
Ïã¸Û´óѧDavid Srolovitz½ÌÊÚ¿ÎÌâ×éÕÐÆ¸¡¸Ïã½Ñ§Õß¡¹²©Ê¿ºó
+1/7
Î人·ÄÖ¯´óѧ½ÜÇàÍŶÓÕÐÑо¿Éú£¨²ÄÁÏ£¬»¯Ñ§£¬¸ß·Ö×Ó£¬»¯¹¤£©
+1/4
323·Ö¿ØÖƹ¤³ÌÇóµ÷¼Á
+1/2
¸£½¨Ê¦·¶´óѧº£Ï¿ÈáÐÔµç×ÓѧԺÕÐÊÕ2026µ÷¼Á˶ʿ
+1/2
¹ú¼Ò½ÜÇàµÍά²ÄÁÏÓëÆ÷¼þÁ¦Ñ§ÍŶÓ2026ÄêÕÐÊÕ²©Ê¿Ñо¿Éú
+1/2
±±¾©´óѧ»·¾³Ñ§ÔºÕÅ×Ó˧Ñо¿Ô±ÕÐÊÕ¿ÆÑÐÖúÀí
+1/1
°®ÓëÓêÏÂ
ÈÙÓþ°æÖ÷ (Ö°Òµ×÷¼Ò)
- ·ÒëEPI: 283
- Ó¦Öú: 10 (Ó×¶ùÔ°)
- ¹ó±ö: 3.592
- ½ð±Ò: 33341.6
- Ìû×Ó: 4644
- ÔÚÏß: 1456.1Сʱ
- ³æºÅ: 535832
ÏÄÌìÏÂÓêÁË(½ð±Ò+1, ·ÒëEPI+1): 2011-03-09 14:54:20
wg423(·ÒëEPI-1): ·ÇÓ¦Öú£¬ÊÕ»ØEPI 2011-03-09 15:29:29
wg423(·ÒëEPI-1): ·ÇÓ¦Öú£¬ÊÕ»ØEPI 2011-03-09 15:29:29
|
ÌåÄÚÍâÏà¹ØÐÔ ÌåÍâÈܳöÊý¾Ý correlation in vivo dissolution data in vitro |
2Â¥2011-03-09 12:29:04
°®ÓëÓêÏÂ
ÈÙÓþ°æÖ÷ (Ö°Òµ×÷¼Ò)
- ·ÒëEPI: 283
- Ó¦Öú: 10 (Ó×¶ùÔ°)
- ¹ó±ö: 3.592
- ½ð±Ò: 33341.6
- Ìû×Ó: 4644
- ÔÚÏß: 1456.1Сʱ
- ³æºÅ: 535832
3Â¥2011-03-09 12:30:25
4Â¥2011-03-09 14:54:01
µØÍ¼ÎÏÅ£
Òø³æ (СÓÐÃûÆø)
- ·ÒëEPI: 9
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 339.4
- Ìû×Ó: 71
- ÔÚÏß: 16.5Сʱ
- ³æºÅ: 804596
5Â¥2011-03-09 16:18:20
µØÍ¼ÎÏÅ£
Òø³æ (СÓÐÃûÆø)
- ·ÒëEPI: 9
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 339.4
- Ìû×Ó: 71
- ÔÚÏß: 16.5Сʱ
- ³æºÅ: 804596
ÏÄÌìÏÂÓêÁË(½ð±Ò+18, ·ÒëEPI+1): лл 2011-03-09 18:10:02
|
¶à¼ÁÁ¿¿Ú·þ10mgÁ½ÖÖÖÆ¼Á£¬Ã¿ÈÕÒ»´Î£¬Ã¿´Î10mg£¬ÓÚ·þÒ©ºóµÚ4ÌìѪҩŨ¶È´ïÎÈ̬¡£Á½ÖÖÖÆ¼ÁµÄFֵΪ98.9%¡À7.9%£¬²ÎÊýTmax£¬Cmax£¬Cmin£¬AUCss£¬AUMCss£¬MRT£¬FIµÈÖ÷ÒªÒ©´ú²ÎÊý½Ó½ü£¬¾·½²îÏÔʾÎÞÏÔÖøÐÔ²îÒ죬½øÒ»²½¾Ë«µ¥²àt¼ìÑéºÍ£¨1-2a£©ÖÃÐÅÇø¼ä·ÖÎöÏÔʾҩ´ú¶¯Á¦Ñ§²ÎÊý½ÓÊÜÉúÎïµÈЧÐÔ¼ÙÉ裬˵Ã÷Á½ÖÖÖÆ¼ÁµÈЧ¡£ Two preparations were oral administrated once per day and 10mg per time. Plasma concentration reached steady state at the fourth day after administration. F value for two preparations was 98.9%¡À7.9%, ANOVA analysis showed no significant differences between two preparations on Tmax£¬Cmax£¬Cmin£¬AUCss£¬AUMCss£¬MRT and FI. Further analysis by two- tailed T-test and (1-2a) confidential interval suggested that pharmacokinetic parameters of two preparations were comparable. ÁÙ´²¹Û²ì£¬ÊÔÑéÆÚ¼äδ¼û²»Á¼·´Ó¦£¬ÎÞÖÐ;ÖÕÖ¹ÊÔÑéµÄÊÜÊÔÕß¡£ No side effects were found during the trial. No subjects quit. ÌåÄÚÍâÏà¹ØÐÔ Correlation between in vitro dissolution and in vivo absorption ÌåÍâÈܳöÊý¾Ý In vitro dissolution test ÒÀ¾ÝÑÐÖÆµ¥Î»Öƶ¨µÄÊͷŶȷ½·¨²â¶¨ÊÔÑ黺ÊͽºÄÒµÄÌåÍâÈܳöÊý¾ÝÈç±í In vitro dissolution test of sustained release capsule was carried out according to the dilution method provided by the producing company. The data was shown in table 1. ÌåÄÚÎüÊÕÊý¾Ý In vivo absorption study ÒÔWanger-Nelson·¨¼ÆËãÊÔÑéÓûºÊͽºÄÒ²»Í¬Ê±¼äµÄÌåÄÚÎüÊÕÊý¾Ý£¬½á¹ûÈç±í ÌåÄÚÎüÊÕÊý¾ÝÓëÌåÍâÈܳö·ÖÊýµÄÏà¹ØÐÔÁ¼ºÃ£¬Ïà¹Ø·½³ÌÈçÏ£º ÌåÄÚÎüÊÕÁ¿%=1.455*ÌåÍâÈܳöÁ¿-12.23 r=0.9638 In vivo absorptions in different time were examined by Wanger-Nelson method. Absorption data were shown in table 2. In vitro dissolution and in vivo absorption were well correlated (In vivo absorption%=1.455* In vitro dissolution-12.23, r=0.9638) |
6Â¥2011-03-09 17:19:44
7Â¥2011-03-09 18:08:13













»Ø¸´´ËÂ¥